The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials

Overview of attention for article published in Frontiers in oncology, February 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 3 news outlets

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 4 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

MRD: Powerful Metric for CLL Research

Medscape, 07 Apr 2023

The latest therapies for chronic lymphocytic leukemia (CLL) offer prolonged remission, along with a need for better tools to…

MRD: Powerful metric for CLL research

Pediatric News , 05 Apr 2023

The latest therapies for chronic lymphocytic leukemia (CLL) offer prolonged remission, along with a need for better tools to…

Challenges in Standardizing Use of MRD Assessment in CLL

AJMC, 27 Mar 2023

As minimal residual disease (MRD) continues to play an increasing prognostic role among a variety of cancers, researchers of a…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.